Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies.

Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE.

Clin Cancer Res. 2019 May 15;25(10):3141-3151. doi: 10.1158/1078-0432.CCR-18-2953. Epub 2019 Feb 8.

PMID:
30737244
2.

Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.

Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR.

Mol Cancer Res. 2019 May;17(5):1036-1048. doi: 10.1158/1541-7786.MCR-18-1026. Epub 2019 Feb 7.

PMID:
30733375
3.

Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features.

Xu B, Reznik E, Tuttle RM, Knauf J, Fagin JA, Katabi N, Dogan S, Aleynick N, Seshan V, Middha S, Enepekides D, Casadei GP, Solaroli E, Tallini G, Ghossein R, Ganly I.

Endocrine. 2019 Apr;64(1):97-108. doi: 10.1007/s12020-019-01848-6. Epub 2019 Jan 28.

PMID:
30689169
4.

EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC.

Krishnamoorthy GP, Davidson NR, Leach SD, Zhao Z, Lowe SW, Lee G, Landa I, Nagarajah J, Saqcena M, Singh K, Wendel HG, Dogan S, Tamarapu PP, Blenis J, Ghossein RA, Knauf JA, Rätsch G, Fagin JA.

Cancer Discov. 2019 Feb;9(2):264-281. doi: 10.1158/2159-8290.CD-18-0606. Epub 2018 Oct 10.

PMID:
30305285
5.

Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.

Dunn LA, Sherman EJ, Baxi SS, Tchekmedyian V, Grewal RK, Larson SM, Pentlow KS, Haque S, Tuttle RM, Sabra MM, Fish S, Boucai L, Walters J, Ghossein RA, Seshan VE, Ni A, Li D, Knauf JA, Pfister DG, Fagin JA, Ho AL.

J Clin Endocrinol Metab. 2019 May 1;104(5):1417-1428. doi: 10.1210/jc.2018-01478.

PMID:
30256977
6.

Radioactive Iodine-Related Clonal Hematopoiesis in Thyroid Cancer Is Common and Associated With Decreased Survival.

Boucai L, Falcone J, Ukena J, Coombs CC, Zehir A, Ptashkin R, Berger MF, Levine RL, Fagin JA.

J Clin Endocrinol Metab. 2018 Nov 1;103(11):4216-4223. doi: 10.1210/jc.2018-00803.

PMID:
30137527
7.

Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes.

Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, Nanjangud G, Eng S, Bose P, Kuo F, Morris LGT, Landa I, Carrillo Albornoz PB, Riaz N, Nikiforov YE, Patel K, Umbricht C, Zeiger M, Kebebew E, Sherman E, Ghossein R, Fagin JA, Chan TA.

Cancer Cell. 2018 Aug 13;34(2):256-270.e5. doi: 10.1016/j.ccell.2018.07.002.

PMID:
30107176
8.

Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease.

Beckham TH, Romesser PB, Groen AH, Sabol C, Shaha AR, Sabra M, Brinkman T, Spielsinger D, McBride S, Tsai CJ, Riaz N, Tuttle RM, Fagin JA, Sherman EJ, Wong RJ, Lee NY.

Thyroid. 2018 Sep;28(9):1180-1189. doi: 10.1089/thy.2018.0214.

PMID:
30105947
9.

Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.

Knauf JA, Luckett KA, Chen KY, Voza F, Socci ND, Ghossein R, Fagin JA.

J Clin Invest. 2018 Aug 31;128(9):4086-4097. doi: 10.1172/JCI120966. Epub 2018 Aug 20.

10.

AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features.

Ferris RL, Nikiforov Y, Terris D, Seethala RR, Ridge JA, Angelos P, Duh QY, Wong R, Sabra MM, Fagin JA, McIver B, Bernet VJ, Harrell RM, Busaidy N, Cibas ES, Faquin WC, Sadow P, Baloch Z, Shindo M, Orloff L, Davies L, Randolph GW.

Head Neck. 2018 Sep;40(9):1881-1888. doi: 10.1002/hed.25141. Epub 2018 Jun 26.

11.

Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.

Marlow LA, Rohl SD, Miller JL, Knauf JA, Fagin JA, Ryder M, Milosevic D, Netzel BC, Grebe SK, Reddi HV, Smallridge RC, Copland JA.

J Clin Endocrinol Metab. 2018 Sep 1;103(9):3169-3182. doi: 10.1210/jc.2017-01845.

PMID:
29846633
12.

Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.

Untch BR, Dos Anjos V, Garcia-Rendueles MER, Knauf JA, Krishnamoorthy GP, Saqcena M, Bhanot UK, Socci ND, Ho AL, Ghossein R, Fagin JA.

Cancer Res. 2018 Aug 15;78(16):4642-4657. doi: 10.1158/0008-5472.CAN-17-1925. Epub 2018 May 14.

PMID:
29760048
13.

Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance.

Tuttle RM, Fagin JA, Minkowitz G, Wong RJ, Roman B, Patel S, Untch B, Ganly I, Shaha AR, Shah JP, Pace M, Li D, Bach A, Lin O, Whiting A, Ghossein R, Landa I, Sabra M, Boucai L, Fish S, Morris LGT.

JAMA Otolaryngol Head Neck Surg. 2017 Oct 1;143(10):1015-1020. doi: 10.1001/jamaoto.2017.1442.

14.

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.

Sherman EJ, Dunn LA, Ho AL, Baxi SS, Ghossein RA, Fury MG, Haque S, Sima CS, Cullen G, Fagin JA, Pfister DG.

Cancer. 2017 Nov 1;123(21):4114-4121. doi: 10.1002/cncr.30861. Epub 2017 Jun 29.

15.

Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia.

Bellelli R, Vitagliano D, Federico G, Marotta P, Tamburrino A, Salerno P, Paciello O, Papparella S, Knauf JA, Fagin JA, Refetoff S, Troncone G, Santoro M.

Mol Cell Endocrinol. 2018 Jan 15;460:24-35. doi: 10.1016/j.mce.2017.06.023. Epub 2017 Jun 23.

16.

Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence.

Ibrahimpasic T, Xu B, Landa I, Dogan S, Middha S, Seshan V, Deraje S, Carlson DL, Migliacci J, Knauf JA, Untch B, Berger MF, Morris L, Tuttle RM, Chan T, Fagin JA, Ghossein R, Ganly I.

Clin Cancer Res. 2017 Oct 1;23(19):5970-5980. doi: 10.1158/1078-0432.CCR-17-1183. Epub 2017 Jun 20.

17.

Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene.

Montero-Conde C, Leandro-Garcia LJ, Chen X, Oler G, Ruiz-Llorente S, Ryder M, Landa I, Sanchez-Vega F, La K, Ghossein RA, Bajorin DF, Knauf JA, Riordan JD, Dupuy AJ, Fagin JA.

Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):E4951-E4960. doi: 10.1073/pnas.1702723114. Epub 2017 Jun 5.

18.

Biologic and Clinical Perspectives on Thyroid Cancer.

Fagin JA, Wells SA Jr.

N Engl J Med. 2016 Dec 8;375(23):2307. doi: 10.1056/NEJMc1613118. No abstract available.

PMID:
27959677
19.

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.

Nagarajah J, Le M, Knauf JA, Ferrandino G, Montero-Conde C, Pillarsetty N, Bolaender A, Irwin C, Krishnamoorthy GP, Saqcena M, Larson SM, Ho AL, Seshan V, Ishii N, Carrasco N, Rosen N, Weber WA, Fagin JA.

J Clin Invest. 2016 Nov 1;126(11):4119-4124. doi: 10.1172/JCI89067. Epub 2016 Sep 26.

20.

Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer.

Deandreis D, Rubino C, Tala H, Leboulleux S, Terroir M, Baudin E, Larson S, Fagin JA, Schlumberger M, Tuttle RM.

J Nucl Med. 2017 May;58(5):717-722. doi: 10.2967/jnumed.116.179606. Epub 2016 Oct 13.

21.

Biologic and Clinical Perspectives on Thyroid Cancer.

Fagin JA, Wells SA Jr.

N Engl J Med. 2016 Sep 15;375(11):1054-67. doi: 10.1056/NEJMra1501993. Review. No abstract available.

22.

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI.

Cancer Cell. 2016 Sep 12;30(3):501-503. doi: 10.1016/j.ccell.2016.08.008. Epub 2016 Sep 12. No abstract available.

23.

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI.

Cancer Cell. 2016 Sep 12;30(3):485-498. doi: 10.1016/j.ccell.2016.06.024. Epub 2016 Aug 11. Erratum in: Cancer Cell. 2016 Sep 12;30(3):501-503.

24.

NADPH Oxidase NOX4 Is a Critical Mediator of BRAFV600E-Induced Downregulation of the Sodium/Iodide Symporter in Papillary Thyroid Carcinomas.

Azouzi N, Cailloux J, Cazarin JM, Knauf JA, Cracchiolo J, Al Ghuzlan A, Hartl D, Polak M, Carré A, El Mzibri M, Filali-Maltouf A, Al Bouzidi A, Schlumberger M, Fagin JA, Ameziane-El-Hassani R, Dupuy C.

Antioxid Redox Signal. 2017 May 20;26(15):864-877. doi: 10.1089/ars.2015.6616. Epub 2016 Aug 22.

25.

Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion.

Dogan S, Wang L, Ptashkin RN, Dawson RR, Shah JP, Sherman EJ, Michael Tuttle R, Fagin JA, Klimstra DS, Katabi N, Ghossein RA.

Mod Pathol. 2016 Sep;29(9):985-95. doi: 10.1038/modpathol.2016.115. Epub 2016 Jun 10.

26.

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.

Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, Taylor BS, Ghossein R, Ganly I, Fagin JA.

J Clin Invest. 2016 Mar 1;126(3):1052-66. doi: 10.1172/JCI85271. Epub 2016 Feb 15.

27.

Alternative transcription initiation leads to expression of a novel ALK isoform in cancer.

Wiesner T, Lee W, Obenauf AC, Ran L, Murali R, Zhang QF, Wong EW, Hu W, Scott SN, Shah RH, Landa I, Button J, Lailler N, Sboner A, Gao D, Murphy DA, Cao Z, Shukla S, Hollmann TJ, Wang L, Borsu L, Merghoub T, Schwartz GK, Postow MA, Ariyan CE, Fagin JA, Zheng D, Ladanyi M, Busam KJ, Berger MF, Chen Y, Chi P.

Nature. 2015 Oct 15;526(7573):453-7. doi: 10.1038/nature15258. Epub 2015 Oct 7.

28.

Response to: Letter to the Editor Regarding the Article "Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma".

Boucai L, Wang LY, Smith AW, Palmer FL, Mahrous A, Tuttle RM, Fagin JA.

Thyroid. 2015 Nov;25(11):1269-70. doi: 10.1089/thy.2015.0369. Epub 2015 Sep 17. No abstract available.

PMID:
26359968
29.

NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.

Garcia-Rendueles ME, Ricarte-Filho JC, Untch BR, Landa I, Knauf JA, Voza F, Smith VE, Ganly I, Taylor BS, Persaud Y, Oler G, Fang Y, Jhanwar SC, Viale A, Heguy A, Huberman KH, Giancotti F, Ghossein R, Fagin JA.

Cancer Discov. 2015 Nov;5(11):1178-93. doi: 10.1158/2159-8290.CD-15-0330. Epub 2015 Sep 10.

30.

Therapy: Lenvatinib and radioiodine-refractory thyroid cancers.

Dunn L, Fagin JA.

Nat Rev Endocrinol. 2015 Jun;11(6):325-7. doi: 10.1038/nrendo.2015.53. Epub 2015 Mar 31. No abstract available.

31.

Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma.

Wang LY, Smith AW, Palmer FL, Tuttle RM, Mahrous A, Nixon IJ, Patel SG, Ganly I, Fagin JA, Boucai L.

Thyroid. 2015 Mar;25(3):300-7. doi: 10.1089/thy.2014.0287. Epub 2014 Dec 16.

PMID:
25386760
32.

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Clifton-Bligh R, Tallini G, Holt EH, Sýkorová V.

J Clin Oncol. 2015 Jan 1;33(1):42-50. doi: 10.1200/JCO.2014.56.8253. Epub 2014 Oct 20.

33.

Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.

Malaguarnera R, Chen KY, Kim TY, Dominguez JM, Voza F, Ouyang B, Vundavalli SK, Knauf JA, Fagin JA.

J Clin Endocrinol Metab. 2014 Oct;99(10):E1976-87. doi: 10.1210/jc.2013-3976. Epub 2014 Jul 16.

34.

External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer.

Romesser PB, Sherman EJ, Shaha AR, Lian M, Wong RJ, Sabra M, Rao SS, Fagin JA, Tuttle RM, Lee NY.

J Surg Oncol. 2014 Sep;110(4):375-82. doi: 10.1002/jso.23656. Epub 2014 Jun 24.

PMID:
24961938
35.

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.

Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA.

Endocr Relat Cancer. 2014 Mar 7;21(2):371-81. doi: 10.1530/ERC-13-0499. Print 2014 Apr. Review.

36.

Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.

Chen X, Makarewicz JM, Knauf JA, Johnson LK, Fagin JA.

Oncogene. 2014 Nov 20;33(47):5442-9. doi: 10.1038/onc.2013.489. Epub 2013 Nov 18.

37.

Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers.

Ricarte-Filho JC, Li S, Garcia-Rendueles ME, Montero-Conde C, Voza F, Knauf JA, Heguy A, Viale A, Bogdanova T, Thomas GA, Mason CE, Fagin JA.

J Clin Invest. 2013 Nov;123(11):4935-44. doi: 10.1172/JCI69766. Epub 2013 Oct 25.

38.

Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation.

Goodwin AF, Tidyman WE, Jheon AH, Sharir A, Zheng X, Charles C, Fagin JA, McMahon M, Diekwisch TG, Ganss B, Rauen KA, Klein OD.

Hum Mol Genet. 2014 Feb 1;23(3):682-92. doi: 10.1093/hmg/ddt455. Epub 2013 Sep 20.

39.

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA.

J Clin Endocrinol Metab. 2013 Sep;98(9):E1562-6. doi: 10.1210/jc.2013-2383. Epub 2013 Jul 5.

40.

Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.

Gild ML, Landa I, Ryder M, Ghossein RA, Knauf JA, Fagin JA.

Endocr Relat Cancer. 2013 Aug 21;20(5):659-67. doi: 10.1530/ERC-13-0085. Print 2013 Oct.

41.

Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression.

Ghossein RA, Katabi N, Fagin JA.

J Clin Endocrinol Metab. 2013 Aug;98(8):E1414-21. doi: 10.1210/jc.2013-1408. Epub 2013 Jun 17.

42.

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V.

JAMA. 2013 Apr 10;309(14):1493-501. doi: 10.1001/jama.2013.3190.

43.

Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy.

Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LG, Liang Y, Socci N, Kannan K, Mo Q, Fagin JA, Chan TA.

J Clin Endocrinol Metab. 2013 May;98(5):E962-72. doi: 10.1210/jc.2012-3539. Epub 2013 Mar 29.

44.

Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.

Sabra MM, Dominguez JM, Grewal RK, Larson SM, Ghossein RA, Tuttle RM, Fagin JA.

J Clin Endocrinol Metab. 2013 May;98(5):E829-36. doi: 10.1210/jc.2012-3933. Epub 2013 Mar 26.

45.

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA.

N Engl J Med. 2013 Feb 14;368(7):623-32. doi: 10.1056/NEJMoa1209288.

46.

Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression.

Ryder M, Gild M, Hohl TM, Pamer E, Knauf J, Ghossein R, Joyce JA, Fagin JA.

PLoS One. 2013;8(1):e54302. doi: 10.1371/journal.pone.0054302. Epub 2013 Jan 23.

47.

Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.

Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA, Rosen N, Fagin JA.

Cancer Discov. 2013 May;3(5):520-33. doi: 10.1158/2159-8290.CD-12-0531. Epub 2013 Jan 29.

48.

Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.

Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, Bhan S, Ho AS, Khan Z, Bishop J, Westra WH, Wood LD, Hruban RH, Tufano RP, Robinson B, Dralle H, Toledo SP, Toledo RA, Morris LG, Ghossein RA, Fagin JA, Chan TA, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Nelkin BD, Ball DW.

J Clin Endocrinol Metab. 2013 Feb;98(2):E364-9. doi: 10.1210/jc.2012-2703. Epub 2012 Dec 21.

49.

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.

Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, Wolchok JD, de Stanchina E, Chandarlapaty S, Poulikakos PI, Fagin JA, Rosen N.

Cancer Cell. 2012 Nov 13;22(5):668-82. doi: 10.1016/j.ccr.2012.10.009.

50.

STAT3 negatively regulates thyroid tumorigenesis.

Couto JP, Daly L, Almeida A, Knauf JA, Fagin JA, Sobrinho-Simões M, Lima J, Máximo V, Soares P, Lyden D, Bromberg JF.

Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):E2361-70. doi: 10.1073/pnas.1201232109. Epub 2012 Aug 13.

Supplemental Content

Loading ...
Support Center